In this study, nanoconjugated vancomycin inhibited the myeloperoxidase activity which was increased due to VRSA infection, suggesting a protective role of nanoconjugated vancomycin (Figure 3). The gene discussed is MPO; the disease is Vancomycin-Resistant Staphylococcus Aureus Infection.